Amgen (NASDAQ:AMGN) Sets New 12-Month High – Here’s What Happened

Amgen Inc. (NASDAQ:AMGN)’s share price hit a new 52-week high during trading on Thursday . The company traded as high as $349.80 and last traded at $349.25, with a volume of 524864 shares. The stock had previously closed at $343.60.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a dividend increase to $2.52, reinforcing its income profile and making the stock more attractive to dividend-focused investors. This supports longer-term investor demand. Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52
• Positive Sentiment: Amgen expanded its obesity/GLP‑1 strategy via a collaboration with Ro, signaling potential new mid-term revenue streams if programs progress. Pipeline progress tends to boost investor sentiment for growth prospects. Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies
• Positive Sentiment: The stock recently hit a 52-week high, reflecting recent buyer interest and validation of recent corporate moves and sentiment around the pipeline. Amgen stock hits 52-week high at $346.41
• Neutral Sentiment: Zacks notes AMGN is a trending stock on its platform, outlining investor attention and search interest but providing no new catalyst; useful context on market interest but not a direct driver. Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
• Neutral Sentiment: Analyst commentary and deep-dive pieces (e.g., Seeking Alpha on MariTide obesity/T2D potential) highlight upside from R&D, but these are longer‑horizon, research-driven views rather than immediate catalysts. Amgen: A Buy In 2026 On Exciting MariTide Obesity – T2D Potential
• Negative Sentiment: Sagebrush has sued Amgen over disputes tied to the 340B program, introducing legal, reimbursement and stakeholder-risk that could pressure margins or create uncertainty around commercial terms. Litigation and policy disputes can weigh on near-term sentiment. Sagebrush sues Amgen over 340B program row
• Negative Sentiment: Sanford C. Bernstein downgraded Amgen to a Hold / lowered its rating, which can trigger selling or reduced conviction among institutional investors and contribute to downward pressure. Bernstein downgrades Amgen (AMGN) to a Hold

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AMGN. Argus lifted their target price on shares of Amgen from $310.00 to $360.00 and gave the company a “buy” rating in a research note on Tuesday, December 30th. Royal Bank Of Canada upped their price objective on Amgen from $330.00 to $335.00 and gave the stock an “outperform” rating in a research note on Thursday, January 8th. The Goldman Sachs Group lifted their target price on Amgen from $400.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Piper Sandler increased their price objective on shares of Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Finally, Daiwa Capital Markets boosted their target price on shares of Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Moderate Buy” and a consensus target price of $339.24.

Amgen Stock Performance

The stock has a market capitalization of $185.64 billion, a PE ratio of 26.64, a PEG ratio of 3.09 and a beta of 0.45. The business’s 50 day moving average is $332.07 and its 200 day moving average is $307.54. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping the consensus estimate of $5.01 by $0.63. The business had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period last year, the company earned $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is currently 77.90%.

Insider Activity

In other news, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 10,908 shares of company stock worth $3,674,966. Company insiders own 0.76% of the company’s stock.

Institutional Trading of Amgen

A number of institutional investors have recently modified their holdings of AMGN. Bridgewater Advisors Inc. lifted its holdings in shares of Amgen by 1.6% during the 4th quarter. Bridgewater Advisors Inc. now owns 2,488 shares of the medical research company’s stock valued at $855,000 after purchasing an additional 40 shares during the last quarter. Bingham Private Wealth LLC acquired a new stake in Amgen in the fourth quarter worth about $495,000. Farther Finance Advisors LLC boosted its holdings in Amgen by 65.5% in the fourth quarter. Farther Finance Advisors LLC now owns 28,191 shares of the medical research company’s stock worth $9,227,000 after acquiring an additional 11,156 shares in the last quarter. Sage Mountain Advisors LLC grew its stake in shares of Amgen by 5.3% during the fourth quarter. Sage Mountain Advisors LLC now owns 5,189 shares of the medical research company’s stock worth $1,698,000 after acquiring an additional 262 shares during the last quarter. Finally, Guidance Capital Inc. increased its holdings in shares of Amgen by 14.9% during the fourth quarter. Guidance Capital Inc. now owns 3,516 shares of the medical research company’s stock valued at $1,220,000 after acquiring an additional 457 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.